keyword
MENU ▼
Read by QxMD icon Read
search

Neuro oncology

keyword
https://www.readbyqxmd.com/read/28441372/assessing-response-of-high-grade-gliomas-to-immune-checkpoint-inhibitors
#1
Solmaz Sahebjam, Dexter G Stallworth, Sepideh Mokhtari, Nam D Tran, John A Arrington
BACKGROUND: Immunotherapeutic agents, especially checkpoint inhibitors, have emerged as the mainstay of therapy for several solid and hematological malignancies. These therapies are under investigation for the treatment of high-grade gliomas and brain metastases. METHODS: This article reviews the unique challenges encountered when evaluating changes on magnetic resonance imaging (MRI) of glioblastomas seen in response to immunotherapy and checkpoint inhibitors and how to effectively incorporate MRI findings into the response assessment of high-grade gliomas to these emerging therapies...
April 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28435297/the-role-of-kpn%C3%AE-1-in-neuro-oncology
#2
EDITORIAL
Megan Lilley, Faris Farassati
No abstract text is available yet for this article.
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28421461/the-role-of-tumor-board-conferences-in-neuro-oncology-a-nationwide-provider-survey
#3
REVIEW
James Snyder, Lonni Schultz, Tobias Walbert
The tumor board or multidisciplinary cancer meeting (MCM) is the foundation of high value multidisciplinary oncology care, coordinating teams of specialists. Little is known on how these meetings are implemented in Neuro-oncology. Benefits of MCMs include coordination, direction for complicated cases, education, and a forum for communication, emerging technology, and clinical trials. This study identifies participation and utilization of neuro-oncology MCMs. A cross-sectional descriptive survey was dispersed through an internet questionnaire...
April 18, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28417344/biotherapy-in-inflammatory-diseases-of-the-cns-current-knowledge-and-applications
#4
REVIEW
Nicolas Collongues, Laure Michel, Jérôme de Seze
Biotherapy represents an innovative therapeutic approach that includes immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell transplants. Their development helps to cross the bridge from bench to bedside and brings new hope of a cure for severe diseases in different fields of medicine. In neurology, a growing range of applications is being developed for these medications. Valuable results are now available in the field of autoimmunity, neuro-oncology, paraneoplastic manifestations, and neurodegenerative disorders...
May 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28410300/applied-cancer-immunogenomics-leveraging-neoantigen-discovery-in-glioblastoma
#5
Tanner M Johanns, Gavin P Dunn
Glioblastoma (GBM) remains a significant cause of cancer-related mortality in pediatric and adult patients with limited treatment options. Immunotherapy represents a promising new therapeutic approach in many solid and hematologic malignancies, including GBM, although only a subset of patients responds clinically. Thus, current efforts are focused on identifying patients most likely to benefit from immune-based therapies. The cancer immunogenomics approach identifies candidate neoantigens from genomics information and represents a potentially exciting new space in precision neuro-oncology...
March 2017: Cancer Journal
https://www.readbyqxmd.com/read/28402497/systematic-review-of-safety-and-cost-effectiveness-of-venous-thromboembolism-prophylaxis-strategies-in-patients-undergoing-craniotomy-for-brain-tumor
#6
Hanna Algattas, Dushyant Damania, Ian DeAndrea-Lazarus, Kristopher T Kimmell, Nicholas F Marko, Kevin A Walter, G Edward Vates, Babak S Jahromi
BACKGROUND: Studies have evaluated various strategies to prevent venous thromboembolism (VTE) in neuro-oncology patients, without consensus. OBJECTIVE: To perform a systematic review with cost-effectiveness analysis (CEA) of various prophylaxis strategies in tumor patients undergoing craniotomy to determine the safest and most cost-effective prophylaxis regimen. METHODS: A literature search was conducted for VTE prophylaxis in brain tumor patients...
April 11, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28397114/neuro-oncology-current-concepts-and-emerging-therapeutics
#7
EDITORIAL
Burt Nabors, John Laterra
No abstract text is available yet for this article.
April 10, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28396845/chromogranin-a-as-a-valid-marker-in-oncology-clinical-application-or-false-hopes
#8
REVIEW
Stavros Gkolfinopoulos, Konstantinos Tsapakidis, Konstantinos Papadimitriou, Demetris Papamichael, Panteleimon Kountourakis
Chromogranin A, due to its primary expression throughout the neuroendocrine system, is a widely accepted biomarker for the assessment of neuro-endocrine tumors. It has been traditionally used in the management of patients with tumors of gastro-enteropancreatic origin. Lately, it has also been implicated in various conditions and diseases, both benign and malignant. However, the paucity of data of adequate strength, as well as its relation with common physiologic conditions and its interaction with commonly prescribed medications, limit its clinical use in only a narrow spectrum...
March 26, 2017: World Journal of Methodology
https://www.readbyqxmd.com/read/28394091/neuro-oncological-ventral-antigen-1-nova1-implications-in-neurological-diseases-and-cancers
#9
REVIEW
Yu Xin, Zheng Li, Heyi Zheng, Jeffery Ho, Matthew T V Chan, William K K Wu
Neuro-oncological ventral antigen 1 (NOVA1) is a RNA-binding protein that interacts with RNA containing repeats of the YCAY sequence. This protein is a brain-specific splicing factor regulating neuronal alternative splicing. It has been increasingly recognized as an important contributor to neurological disorders and carcinogenesis. In this review, we summarize the biological functions and pathological roles of NOVA1. The clinical implications of NOVA1 will also be discussed.
April 10, 2017: Cell Proliferation
https://www.readbyqxmd.com/read/28391300/meeting-update-society-for-neuro-oncology-2016-annual-meeting
#10
Roy E Strowd, Albert H Kim
No abstract text is available yet for this article.
February 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28391295/diagnosis-and-treatment-of-brain-metastases-from-solid-tumors-guidelines-from-the-european-association-of-neuro-oncology-eano
#11
Riccardo Soffietti, Ufuk Abacioglu, Brigitta Baumert, Stephanie E Combs, Sara Kinhult, Johan M Kros, Christine Marosi, Philippe Metellus, Alexander Radbruch, Salvador S Villa Freixa, Michael Brada, Carmine M Carapella, Matthias Preusser, Emilie Le Rhun, Roberta Rudà, Joerg C Tonn, Damien C Weber, Michael Weller
The management of patients with brain metastases has become a major issue due to the increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014, the European Association of Neuro-Oncology (EANO) created a multidisciplinary Task Force to draw evidence-based guidelines for patients with brain metastases from solid tumors. Here, we present these guidelines, which provide a consensus review of evidence and recommendations for diagnosis by neuroimaging and neuropathology, staging, prognostic factors, and different treatment options...
February 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28387340/advances-in-neuro-oncology-imaging
#12
REVIEW
Karl-Josef Langen, Norbert Galldiks, Elke Hattingen, Nadim Jon Shah
Despite the fact that MRI has evolved to become the standard method for diagnosis and monitoring of patients with brain tumours, conventional MRI sequences have two key limitations: the inability to show the full extent of the tumour and the inability to differentiate neoplastic tissue from nonspecific, treatment-related changes after surgery, radiotherapy, chemotherapy or immunotherapy. In the past decade, PET involving the use of radiolabelled amino acids has developed into an important diagnostic tool to overcome some of the shortcomings of conventional MRI...
April 7, 2017: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/28385884/classification-of-high-grade-glioma-into-tumor-and-nontumor-components-using-support-vector-machine
#13
D T Blumenthal, M Artzi, G Liberman, F Bokstein, O Aizenstein, D Ben Bashat
BACKGROUND AND PURPOSE: Current imaging assessment of high-grade brain tumors relies on the Response Assessment in Neuro-Oncology criteria, which measure gross volume of enhancing and nonenhancing lesions from conventional MRI sequences. These assessments may fail to reliably distinguish tumor and nontumor. This study aimed to classify enhancing and nonenhancing lesion areas into tumor-versus-nontumor components. MATERIALS AND METHODS: A total of 140 MRI scans obtained from 32 patients with high-grade gliomas and 6 patients with brain metastases were included...
April 6, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28367251/milestones-of-the-last-10%C3%A2-years-cns-cancer
#14
REVIEW
Christine Marosi, Matthias Preusser
For neuro-oncologists, much was accomplished in the last decade, including the establishment of the first standard of care (SOC) in this field of oncology. New treatment options boosted research in the whole field of neuro-oncology, as well clinical trials, translational and basic research. Accumulated data on molecular-genetic subgroups with distinct clinical outcomes in disease entities led to the establishment of new biomarkers and to the collaborative formulation of a new WHO classification of central nervous system tumors...
2017: Memo
https://www.readbyqxmd.com/read/28362934/three-dimensional-printed-modeling-of-diffuse-low-grade-gliomas-and-associated-white-matter-tract-anatomy
#15
Jayesh P Thawani, Nickpreet Singh, Jared M Pisapia, Kalil G Abdullah, Drew Parker, Bryan A Pukenas, Eric L Zager, Ragini Verma, Steven Brem
BACKGROUND: Diffuse low-grade gliomas (DLGGs) represent several pathological entities that infiltrate and invade cortical and subcortical structures in the brain. OBJECTIVE: To describe methods for rapid prototyping of DLGGs and surgically relevant anatomy. METHODS: Using high-definition imaging data and rapid prototyping technologies, we were able to generate 3 patient DLGGs to scale and represent the associated white matter tracts in 3 dimensions using advanced diffusion tensor imaging techniques...
April 1, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28361932/neuro-oncology-cd47-antibody-helps-phagocytes-fight-paediatric-cancer
#16
Charlotte Ridler
No abstract text is available yet for this article.
March 31, 2017: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/28349351/advanced-mri-techniques-in-the-monitoring-of-treatment-of-gliomas
#17
REVIEW
Harpreet Hyare, Steffi Thust, Jeremy Rees
With advances in treatments and survival of patients with glioblastoma (GBM), it has become apparent that conventional imaging sequences have significant limitations both in terms of assessing response to treatment and monitoring disease progression. Both 'pseudoprogression' after chemoradiation for newly diagnosed GBM and 'pseudoresponse' after anti-angiogenesis treatment for relapsed GBM are well-recognised radiological entities. This in turn has led to revision of response criteria away from the standard MacDonald criteria, which depend on the two-dimensional measurement of contrast-enhancing tumour, and which have been the primary measure of radiological response for over three decades...
March 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28345737/-meningeal-carcinomatosis-in-breast-cancer-from-diagnosis-to-treatment
#18
REVIEW
C Elm'hadi, Z Es Sbai, M Reda Khmamouche, M Toreis, R Tanz, H Errihani, M Ichou
The appearance of meningeal carcinomatosis in breast cancer is an event that is being reported increasingly more frequently in the literature. It seems to be related with the lengthening of the patients' lives, improved sensitivity to diagnostic imaging and impermeability of the blood-brain barrier to the chemotherapeutic agents. It is an evolutionary form that affirms the metastatic invasion of the subarachnoidal space and is correlated with limited survival. Its diagnosis is difficult, due to the lack of specificity of the clinical signs dominated by headaches, cognitive disorders and possible signs and symptoms of progressive focal lesions...
April 1, 2017: Revista de Neurologia
https://www.readbyqxmd.com/read/28325997/a-comprehensive-approach-in-high-grade-glioma-management-position-statement-from-the-neuro-oncology-scientific-club-nosc-shiraz-iran
#19
REVIEW
Mansour Ansari, Ahmad Mosalaei, Niloufar Ahmadloo, Alireza Rasekhi, Bita Geramizadeh, Ali Razmkon, Kazem Anvari, Mohammad Afarid, Ali Dadras, Leila Nafarieh, Mohammad Mohammadianpanah, Hamid Nasrolahi, Seyed Hasan Hamedi, Shapour Omidvari, Mohammad Nami
Establishing a robust teamwork model in the practice of neuro-oncology requires continued interdisciplinary efforts. The Neuro-Oncology Scientific Club (NOSC) initiative is an interdisciplinary clinical forum promoting the comprehensive approach across involved disciplines in the management of central nervous system (CNS) malignancies. With its provincial founding panels and national steering board, NOSC has been operational in Iran since 2011. This initiative has pursued its mission through interval strategic meetings, tumor boards, case discussions as well as publishing neuro-oncology updates, case study periodicals, and newsletters...
2017: German Medical Science: GMS E-journal
https://www.readbyqxmd.com/read/28321824/therapeutic-hypothesis-testing-with-rodent-brain-tumor-models
#20
REVIEW
Derek A Wainwright, Craig M Horbinski, Rintaro Hashizume, C David James
The development and application of rodent models for preclinical testing of novel therapeutics and approaches for treating brain tumors has been a mainstay of neuro-oncology preclinical research for decades, and is likely to remain so into the foreseeable future. These models serve as an important point of entry for analyzing the potential efficacy of experimental therapies that are being considered for clinical trial evaluation. Although rodent brain tumor models have seen substantial change, particularly since the introduction of genetically engineered mouse models, certain principles associated with the use of these models for therapeutic testing are enduring, and form the basis for this review...
March 20, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
keyword
keyword
14974
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"